StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Women in Executive Roles by Year

Women in Executive Roles (legacy ESG report disclosure) (%) (%)

Amgen Women in Executive Roles: 44.0% in FY2023, down 1.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, FY2023
44.0%
Period ended Dec 31, 2023
Change on a year earlier
-1.0 pts
45.0% in FY2022
History
5 years
Since FY2019
Sources
1
https://www.responsibilityreports.com/HostedData/ResponsibilityReportArchive/a/NASDAQ_AMGN_2023.pdf

Where the FY2023 figure comes from

“% of Women Executive Level ** People 39 42 44 45 44”

Reported in Amgen Sustainability Report.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Amgen Women in Executive Roles (%), annual FY2019–FY2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/esg-div-women-exec

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.